A Registry Study of Participants With Multiple Myeloma in Latin America
NCT ID: NCT03955900
Last Updated: 2023-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2059 participants
OBSERVATIONAL
2019-05-29
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain
NCT03602755
Multiple Myeloma Patient Registry
NCT03180853
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
NCT05001087
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00995059
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
NCT01241396
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with Multiple Myeloma (MM)
Participants with MM will be observed in real-world clinical practice settings. The primary data source for this study will be the medical records of each participant.
No intervention
Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An informed-consent form (ICF) or participation agreement must be signed before any data are collected only if a waiver is not permissible. For deceased participants who did not provide consent before death, the permission to research on their information should satisfy the local requirements (that each study site's ethics committee and each country's regulatory authority)
* Only with diagnosis of smouldering myeloma between 01 January 2016 and 31 December 2020 in the medical charts
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen-Cilag Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen-Cilag Ltd. Clinical Trial
Role: STUDY_DIRECTOR
Janssen-Cilag Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundaleu
Buenos Aires, , Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, , Argentina
Instituto de Oncologia Angel H. Roffo
Buenos Aires, , Argentina
Hospital Privado - Centro Medico de Cordoba
Córdoba, , Argentina
Hospital Italiano de La Plata
La Plata, , Argentina
Fundacao para o Desenvolvimento Medico Hospitalar (UNESP Botucatu)
Botucatu, , Brazil
Liga Norte Riograndense Contra O Cancer
Natal, , Brazil
Hospital das Clinicas de Porto Alegre
Porto Alegre, , Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
Rio de Janeiro, , Brazil
CEHON
Salvador, , Brazil
Clinica Sao Germano
São Paulo, , Brazil
Fundação Antônio Prudente - A.C. Camargo Cancer Center
São Paulo, , Brazil
SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo
São Paulo, , Brazil
Instituto de Assistencia Medica ao Servidor Publico Estadual - IAMSPE
São Paulo, , Brazil
Hospital Universitario Mayor - Mederi
Bogotá, , Colombia
Fundacion Santa Fe de Bogota
Bogotá, , Colombia
Clinica de Occidente
Cali, , Colombia
Fundacion Oftalmologica de Santander - FOSCAL
Floridablanca, , Colombia
Hospital Pablo Tobon Uribe
Medellín, , Colombia
Centro de Investigación Farmacéutica Especializada
Guadalajara, , Mexico
Hospital Angeles Lomas
Huixquilucan, , Mexico
Centro Hemato Oncologico Paitilla
Panama City, , Panama
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hungria V, Gaiolla R, Galvez K, Remaggi G, Schutz N, Bittencourt R, Maiolino A, Quintero-Vega G, Cugliari MS, Braga WMT, Villarim CC, Crusoe E, Enrico AI, Caiero G, Bigonha J, Moura FL, Figueroa J, Sossa Melo CL, Lombana M, Pei H, Fernandez M, Saes J, Trufelli DC. Health care systems as determinants of outcomes in multiple myeloma: final results from the Latin American MYLACRE study. Blood Adv. 2025 Mar 25;9(6):1293-1302. doi: 10.1182/bloodadvances.2024013838.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
54767414MMY4021
Identifier Type: OTHER
Identifier Source: secondary_id
CR108622
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.